A study reported by Yasuhito Tanaka of the Nagoya City University Medical Department in Japan showed that the single nucleotide polymorphism (SNP) in the TLL1 gene is related to the occurrence and development of hepatocellular carcinoma after radical cure of hepatitis C virus infection. (Gastroenterology. 2017, 152: 1383-1394.) The researchers established different models by combining TLL1 gene mutation with other significant risk factors to predict the risk of liver cancer in patients with different degrees of liver fibrosis. TLL1 gene variants can be used to predict the risk of ailse ae in patients who have achieved a sustained virological response (SVR) in clinical practice. The study included Japanese patients who still suffered from liver cancer after interferon eradication of hepatitis C virus, and used genome-wide association analysis to identify which genes were mutated. The results showed that the TNP1 gene SNP rs17047200 on chromosome 4 is closely related to the occurrence of liver cancer after eradication of hepatitis C virus. There is no obvious linkage disequilibrium between other SNPs and rs17047200, and no more promising SNPs have been found in the exons and promoter regions of TLL1. Tanaka commented: “The mutant genes of liver cancer caused by hepatitis C virus include MICA and DEPDC5, which is very different from our test results.” In a multivariate analysis, the AT / TT base pairing of rs17047200 may lead to a 78% increased risk of liver cancer (P = 0.008). In the group of patients with mild fibrosis, older age is an independent risk factor for liver cancer; in the group of severe fibrosis, postoperative alpha-fetoprotein level and low albumin level are also risk factors. In two groups of liver fibrosis rat models, the mRNA level of TLL1 has increased, but only one group of models of TLL1 mRNA level is consistent with the progress of liver fibrosis. The level of TLL1 mRNA in patients with chronic hepatitis C also increases as liver fibrosis worsens.
Dúirt Tananka: “Léiríonn na sonraí seo ar dtús an gaol idir slonn TLL1 / Tll1 agus gníomhachtú cille stellate hepatic nó dul chun cinn fiobróis hepatic in ainmhithe nó in vitro agus i ndaoine (is é an tsamhail ailse ae a bhaineann le steatohepatitis neamh-alcólach). D'fhéadfadh sé a bheith in ann meicníocht nua fiobróis ae nó ailse a shoiléiriú. Tar éis don othar cóireáil radacach a fháil le haghaidh víreas heipitíteas C agus SVR a fháil, féadfar turgnaimh a bhaineann le TLL1 SNP a úsáid chun daoine atá i mbaol ailse ae a aithint. Má dhéantar comparáid idir TLL1 SNP agus TLL1 Is féidir leis an meascán d'aois, leibhéal fiobróis, leibhéal ard alfa-fetoprotein agus fachtóirí riosca suntasacha eile cabhrú le réamh-mheas cliniciúil a dhéanamh ar an mbaol ailse ae tar éis SVR. Níl plean cóireála béil interferon in éineacht le teiripe drugaí frithvíreasach atá ag gníomhú go díreach , Ag éirí mar theiripe víreas caighdeánach frith-heipitíteas C i dtíortha forbartha. Mar sin féin, tá gá le tuilleadh taighde chun a mheas an bhfuil baint ag sócháin TLLXNUMX le tarlú ailse ae tar éis cóireála le SVR saor ó interferon.
